Europe Molecular Diagnostics Market to Reach USD 17.3 Billion by 2034, Growing at 10.2% CAGR

The molecular diagnostics industry in Europe was valued at USD 5.9 Bn in 2023 and is projected to reach USD 17.3 Bn by the end of 2034, expanding at a CAGR of 10.2% from 2024 to 2034. Market growth is driven by rising incidence of infectious and chronic diseases, increasing demand for personalized medicine, growing adoption of advanced molecular testing technologies, and strong regional healthcare investments in early diagnostics.

👉 Get a sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=9434

Market Overview

Molecular diagnostics encompasses laboratory techniques used to analyze biological markers in the genome and proteome, allowing clinicians to diagnose diseases, assess risk, and monitor treatment response at a molecular level.

Common technology and product types include Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), In Situ Hybridization (ISH), and microarray assays, alongside associated reagents, instruments, and software. These tools help detect genetic mutations, infectious pathogens, and oncological biomarkers with high sensitivity and specificity.

An aging European population and high frequencies of cancer, cardiovascular conditions, and emerging viral pathogens are supporting demand for high-performance diagnostic solutions. Stricter clinical demands for precision oncology and targeted therapies are also encouraging healthcare systems and laboratories to improve testing turnaround times and throughput capabilities.

The growing integration of digital pathology, automation, and bioinformatics into clinical laboratories is creating new requirements for molecular infrastructure. Manufacturers and specialized diagnostic firms are therefore focusing on scalable, high-throughput, and user-friendly testing platforms.
Analysts' Viewpoint

Analysts expect the European molecular diagnostics market to expand rapidly as clinical laboratories and hospitals continue modernizing infrastructure to meet clinical and public health requirements. Demand for automated PCR systems and advanced NGS panels is expected to increase as decentralized testing and biomarker profiling become more critical.

Reference laboratories and specialized oncology centers also represent important growth opportunities, supported by routine and complex diagnostic screening. Meanwhile, the transition toward companion diagnostics and personalized oncology is encouraging industry participants to develop targeted assay panels for emerging therapeutic indications.

Analysis of Key Players

• Leading diagnostic corporations are developing high-throughput automated PCR and NGS instrument platforms.

• Companies are investing in companion diagnostic (CDx) development to support targeted cancer immunotherapies and therapies.

• Organizations are expanding reagent and assay kit portfolios for rapid infectious disease detection and respiratory panels.

• Industry participants are strengthening strategic partnerships with regional hospital networks, clinical laboratories, and research institutions.

• Companies are focusing on decentralized point-of-care molecular testing solutions to enhance accessibility across European healthcare systems.

Recent Developments (2023-2024)

• Molecular diagnostic manufacturers have continued launching advanced high-throughput multiplex PCR systems with reduced hands-on time.

• Organizations have increased investments in European manufacturing facilities and logistics hubs to secure regional supply chains.

• Providers have expanded regulatory approvals for oncology and infectious disease assay panels under updated European frameworks (such as IVDR).

• Industry participants have established collaborative agreements with pharmaceutical developers to co-develop companion diagnostic tests.

👉 Get sample market research report copy today@ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=9434

Key Developments & Trends

• Next-Generation Sequencing (NGS): Increasing clinical adoption of NGS is driving comprehensive genomic profiling for oncology and rare diseases.

• Infectious Disease Testing: Ongoing demand for fast multiplex panels continues to shape hospital and public health laboratory workflows.

• Decentralized Testing: Growing preference for near-patient and point-of-care molecular systems is expanding access outside central labs.

• Regulatory Compliance: Implementation of the In Vitro Diagnostic Regulation (IVDR) is driving rigorous clinical validation standards across the region.

Challenges

• Strict Regulatory Frameworks: Complex and lengthy compliance processes under EU IVDR guidelines can delay commercialization and product availability.

• High Infrastructure Costs: Substantial capital investments required for advanced NGS and automation equipment can strain healthcare facility budgets.

• Reimbursement Complexities: Varying reimbursement policies across different European countries can impact market adoption rates for novel genomic tests.

• Data Security Concerns: Managing sensitive patient genomic data requires robust cybersecurity measures and strict adherence to privacy regulations.

Opportunities

• Companion Diagnostics: Growth in targeted cancer therapies creates strong opportunities for co-developed molecular screening tools.

• Point-of-Care Molecular Solutions: Development of rapid, cartridge-based systems offers potential for decentralized testing in clinics and physician offices.

• AI and Bioinformatics: Integration of artificial intelligence tools provides avenues for automated variant interpretation and streamlined reporting.

• Expanded Screening Programs: Implementation of population-wide genetic and infectious disease screening initiatives supports sustained reagent demand.

Market Segmentation

• By Technology: Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), In Situ Hybridization (ISH), Microarrays, Others
• By Application: Infectious Diseases, Oncology, Pharmacogenomics, Genetic Disorders, Neurology, Others
• By Product & Service: Reagents & Kits, Instruments, Software & Services
• By End User: Hospitals & Academic Medical Centers, Reference Laboratories, Point-of-Care Settings, Research Institutes, Others
• By Region (Country-Level Analysis): Germany, France, United Kingdom, Italy, Spain, Rest of Europe

Conclusion

The Europe molecular diagnostics market is projected to grow from USD 5.9 Bn in 2023 to USD 17.3 Bn by 2034, advancing at a CAGR of 10.2% from 2024 to 2034. Rising chronic and infectious disease burdens, high demand for personalized medicine, and technological advancements in genomics and automation are expected to remain key market growth drivers. Advances in NGS, companion diagnostics, and point-of-care molecular platforms are likely to create new opportunities for industry participants as precision healthcare continues to evolve across Europe.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=9434

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com

This release was published on openPR.